Document is current
Any future updates will be listed below
-
Authors
Soares, Marta http://orcid.org/0000-0002-6071-3673
Antunes, Luís http://orcid.org/0000-0002-3098-0711
Redondo, Patrícia http://orcid.org/0000-0001-8560-1646
Borges, Marina http://orcid.org/0000-0002-8073-6506
Hermans, Ruben
Patel, Dony
Grimson, Fiona
Munro, Robin
Chaib, Carlos
Lacoin, Laure
Daumont, Melinda
Penrod, John R.
O’Donnell, John C.
Bento, Maria José http://orcid.org/0000-0002-7690-9830
Rocha Gonçalves, Francisco
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb Company (N/A)
- License Information
-
More Information
Article History
Received: 30 April 2020
Accepted: 19 August 2020
First Online: 10 September 2020
Ethics approval and consent to participate
: This study was conducted in accordance with the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Epidemiology Practices and the ethical principles that have their origin in the Declaration of Helsinki. The laws and regulatory requirements in Portugal were followed. The protocol received approval by the Institutional Review Board (IRB; Ethics Committee of the Portuguese Oncology Institute of Porto). This was a retrospective observational study using anonymised patient data. Patients were not contacted or directly impacted by study participation in any way, thus obtaining informed consent was not applicable.
: Not applicable.
: MS, LA, PR, MB, and MJB are employees of IPO-Porto.MB received personal fees and non-financial support from Roche and non-financial support from Janssen outside the submitted work.FRG has no competing interests.RH, DP, FG, and RM are employees of IQVIA.CC, MD, JRP, and JCO are employees of Bristol Myers Squibb.CC and JRP report stock ownership in Bristol Myers Squibb.LL was contracted (paid) as consultant by Bristol Myers Squibb to support the I-O Optimise initiative and is an employee of Epi-Fit.
